Dr. Ayman Al Jurdi
Doha: A Weill Cornell Medicine-Qatar (WCM-Q) alumnus has been awarded a grant by a leading pharmaceutical company for a research project to investigate the impact of an anti-COVID-19 drug on recipients of organ transplants.
Dr. Ayman Al Jurdi, who graduated from WCM-Q in 2015, is currently a transplant nephrology fellow at Massachusetts General Hospital (MGH), one of the most highly ranked healthcare institutions in the US.
His principal clinical and research interests are prevention of infections in immunocompromised kidney transplant patients, treatment of antibody-mediated rejection in kidney transplant patients, and treatment of antibody-mediated diseases of the glomeruli, clusters of tiny blood vessels within the kidneys where blood is filtered to extract waste for excretion.
Dr. Al Jurdi received the award from the multinational pharmaceutical company AstraZeneca for his grant proposal for a study of the efficacy of Evusheld - a medication used to prevent COVID-19 in adults and adolescents who are immunocompromised due to medical conditions or immunosuppressive medications – for patients who have had an organ transplant.
